Questa pagina è stata tradotta automaticamente e l'accuratezza della traduzione non è garantita. Si prega di fare riferimento al Versione inglese per un testo di partenza.

A Study Evaluating the Impact of a Painkiller Product on Quality-of-Life and Daily Functioning

16 novembre 2026 aggiornato da: HALEON

A Multi-country, Retrospective, Real World Observational Study Evaluating the Impact of an Analgesic Product on Quality-of-Life and Daily Functioning

The aim of this study is to generate real-world, consumer reported evidence on the perceived impact of headache relief with Panadol/Dolex on Quality of Life (QoL) and daily functioning.

Panoramica dello studio

Stato

Non ancora reclutamento

Condizioni

Intervento / Trattamento

Descrizione dettagliata

This is a multi-country, real-world, observational, cross-sectional survey study. The target population for this survey study comprises individuals who have used Panadol/Dolex for the relief of more than or equal to (>=)1 headache episode in the past 1 month. Eligible participants will be directed to complete an online survey comprising of a series of questions designed to gather data relevant to the research objectives. The study population will be comprised of approximately 2,100 participants across Australia, Malaysia, Colombia, and Kenya.

Tipo di studio

Osservativo

Iscrizione (Stimato)

2100

Contatti e Sedi

Questa sezione fornisce i recapiti di coloro che conducono lo studio e informazioni su dove viene condotto lo studio.

Contatto studio

Luoghi di studio

    • Marina Centre
      • Singapore, Marina Centre, Singapore
        • Virtual site

Criteri di partecipazione

I ricercatori cercano persone che corrispondano a una certa descrizione, chiamata criteri di ammissibilità. Alcuni esempi di questi criteri sono le condizioni generali di salute di una persona o trattamenti precedenti.

Criteri di ammissibilità

Età idonea allo studio

18 anni e precedenti (Adulto, Adulto più anziano)

Accetta volontari sani

No

Sessi ammissibili allo studio

Tutto

Metodo di campionamento

Campione non probabilistico

Popolazione di studio

Residents of Australia, Malaysia, Colombia, Kenya who have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month and have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.

Descrizione

Inclusion Criteria:

  • Residents of Australia, Malaysia, Colombia, Kenya.
  • Have experienced acute primary headaches that occur 1 to 14 days a month on average in the past 1 month.
  • Have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.
  • Self-reported healthy individuals.
  • Able to provide informed consent.
  • The specific Panadol/Dolex variant for each country as applicable.

Exclusion Criteria:

  • Participants who experience headaches that occur 15 or more days per month.
  • Participants with migraine.
  • Participants who use any headache medication, pain relief product or alternative remedy (herbal products, supplements, CBD [cannabidiol]- containing pain remedies) concurrently with Panadol/Dolex for the recalled headache episode in the past 1 month.
  • Participants diagnosed by a healthcare professional with chronic pain conditions (fibromyalgia, neuropathic pain, cancer, lupus, multiple sclerosis) who were experiencing symptoms or receiving treatment for the condition at the time of reference headache episode when Panadol/Dolex was used.
  • Breastfeeding or Pregnant at the time of reference headache episode during which Panadol/Dolex was used.
  • Participants affiliated with Sponsor or Contract Research Organization (CRO).

Piano di studio

Questa sezione fornisce i dettagli del piano di studio, compreso il modo in cui lo studio è progettato e ciò che lo studio sta misurando.

Come è strutturato lo studio?

Dettagli di progettazione

  • Modelli osservazionali: COHORT
  • Prospettive temporali: CROSS_SECTIONAL

Coorti e interventi

Gruppo / Coorte
Intervento / Trattamento
Panadol/Dolex Tablet

Participants who have taken Panadol/Dolex for at least 1 headache episode in the past 1 month.

Paracetamol 500 milligram (mg) taken orally.

Cosa sta misurando lo studio?

Misure di risultato primarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Pain Intensity Before Using Panadol/Dolex
Lasso di tempo: Within the past 1 month from time of participation

Thinking about most recent headache episode, participants will be asked to rate the pain intensity experienced before using Panadol/Dolex on a scale 0 to 10, where 0= No pain and 10= Worst possible pain. Lower score indicates better outcome.

Within the past 1 month from time of participation
Perceived Relief From Panadol/Dolex Use
Lasso di tempo: Within the past 1 month from time of participation

Thinking about the headache episode, participants will describe the first sign of symptom relief they perceived after taking Panadol/Dolex.

Within the past 1 month from time of participation
QoL Assessment After Using Panadol/Dolex Post Headache Episode
Lasso di tempo: Within the past 1 month from time of participation

Thinking about most recent headache episode, participants will be asked to respond to 10 questions related to aspects of daily life when they used Panadol/Dolex after headache episode. The response will be scored using a 5-point scale, where 1= Not at all, and 5= Very Much. Lower score indicates better quality of life.

Within the past 1 month from time of participation

Misure di risultato secondarie

Misura del risultato
Misura Descrizione
Lasso di tempo
Frequency of Panadol/Dolex Use
Lasso di tempo: Within the past 1 month from time of participation

Thinking about the recent headache episode, participants will be asked to mention the frequency of product use from 1 time a day to 4 times a day.

Within the past 1 month from time of participation
Timepoint of Panadol/Dolex Use
Lasso di tempo: Within the past 1 month from time of participation

Participants will answer a single question related to timepoint of product use- 'Thinking about the same headache episode which you used Panadol for relief in the past one month, what did you first do to relieve the pain?' Participants will choose one of the given options.

Within the past 1 month from time of participation
Product Satisfaction
Lasso di tempo: Within the past 1 month from time of participation

Thinking about the experience of using Panadol, participants will rate their overall satisfaction on a scale 1 to 5, where 1= Absolutely dissatisfied and 5= Completely satisfied.

Within the past 1 month from time of participation
Headache Management Behaviors
Lasso di tempo: Within the past 1 month from time of participation

Participants will answer a single question related to headache management approaches they used before- 'Thinking about similar headaches you experienced before this episode, what did you do to relieve your headache in the past?' Participants will select one or more descriptive options provided.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Trust in The Product
Lasso di tempo: Within the past 1 month from time of participation

Participants will answer a single question related to trust in the product- 'How much do you trust the product to provide fast headache pain relief?' Participants will choose one of the given options.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Value For Money
Lasso di tempo: Within the past 1 month from time of participation

Thinking about experience of using the product, participants will be asked to rate the product's value for money on a scale 1 to 5, where 1= Poor value for money and 5= Excellent value for money.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Use Again
Lasso di tempo: Within the past 1 month from time of participation

Participants will answer a single question related to continued purchase- 'How likely would you choose Panadol again for your next headache episode?'. Participants will choose one of the given options.

Within the past 1 month from time of participation
User Attitudes Towards Panadol/Dolex: Intention to Recommend Other Consumers
Lasso di tempo: Within the past 1 month from time of participation

Participants will answer a single question related to likelihood to recommend others- How likely would you recommend Panadol to other consumers experiencing headache pain? Participants will choose one of the given options.

Within the past 1 month from time of participation

Collaboratori e investigatori

Qui è dove troverai le persone e le organizzazioni coinvolte in questo studio.

Sponsor

Studiare le date dei record

Queste date tengono traccia dell'avanzamento della registrazione dello studio e dell'invio dei risultati di sintesi a ClinicalTrials.gov. I record degli studi e i risultati riportati vengono esaminati dalla National Library of Medicine (NLM) per assicurarsi che soddisfino specifici standard di controllo della qualità prima di essere pubblicati sul sito Web pubblico.

Studia le date principali

Inizio studio (Stimato)

1 dicembre 2026

Completamento primario (Stimato)

1 gennaio 2027

Completamento dello studio (Stimato)

1 gennaio 2027

Date di iscrizione allo studio

Primo inviato

16 ottobre 2026

Primo inviato che soddisfa i criteri di controllo qualità

26 ottobre 2026

Primo Inserito (Effettivo)

2 novembre 2026

Aggiornamenti dei record di studio

Ultimo aggiornamento pubblicato (Effettivo)

17 novembre 2026

Ultimo aggiornamento inviato che soddisfa i criteri QC

16 novembre 2026

Ultimo verificato

1 novembre 2026

Maggiori informazioni

Termini relativi a questo studio

Piano per i dati dei singoli partecipanti (IPD)

Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?

SÌ

Descrizione del piano IPD

Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Periodo di condivisione IPD

IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Criteri di accesso alla condivisione IPD

Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

Tipo di informazioni di supporto alla condivisione IPD

  • STUDIO_PROTOCOLLO
  • LINFA
  • ICF

Informazioni su farmaci e dispositivi, documenti di studio

Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti

No

Studia un dispositivo regolamentato dalla FDA degli Stati Uniti

No

Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .

Sottoscrivi